Regulatory Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug BioSpaceThe FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency.Rare DiseaseRead full story pharminent June 10, 2026 (Last updated: June 10, 2026) BioSpace The FDA rejected bitopertin in February amid reports of skepticism from former CBER director Vinay Prasad, who has since departed the agency. Rare Disease Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Bayer’s asundexian starts EU review for ischaemic strokeNext: Lilly wins new FDA approval for eczema drug Ebglyss Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
